33 Results

People

  1. Lesokhin
    Lesokhin
  2. Wolchok
    Wolchok
  3. Postow
    Postow
  4. Callahan
    Callahan
  5. Segal
    Segal
  6. Merghoub
    Merghoub
  7. Gordon
    Gordon
  8. Kitano
    Kitano
  9. Yuan
    Yuan
  10. Hirschhorn Cymerman
    Hirschhorn Cymerman

Groups

  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. Hematologic Malignancies Research (33)
  4. Hematologic Malignancies, Division of (33)
  5. Melanoma and Immunotherapeutics Service (33)
  6. Myeloma (33)
  7. Solid Tumor Oncology Division (33)
  8. GSK Faculty (29)
  9. Melanoma Disease Management Team (22)
  10. Gastrointestinal Oncology Service (12)
  1. "Hematologic Malignancies Research"
  2. "Myeloma"
  3. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (19)
  2. Meeting Abstract (11)
  3. Book Section (3)
Groups
  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. Hematologic Malignancies Research (33)
  4. Hematologic Malignancies, Division of (33)
  5. Melanoma and Immunotherapeutics Service (33)
  6. Myeloma (33)

More Groups

People
  1. Alexander Lesokhin (29)
  2. Jedd Wolchok (29)
  3. Michael Postow (16)
  4. Margaret Callahan (14)
  5. Neil Segal (10)
  6. Taha Merghoub (9)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (1)
  5. 2016 (4)
  6. 2015 (3)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Journal of Experimental Medicine (4)
  3. Blood (3)
  4. Pocket Oncology (3)
  5. Cancer Immunology Research (2)
  6. European Journal of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Rockefeller University Press (4)
  3. American Association for Cancer Research (3)
  4. American Society of Hematology (3)
  5. Elsevier Inc. (3)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (3)

More Publishers

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma
    Meeting Abstract

    Atkins, M. B.; Kirkwood, J. M.; Wolchok, J. D.; Callahan, M. K.; Kluger, H. M.; Postow, M. A.; Segal, N. H.; Lesokhin, A. M.; Balogh, A.; Re, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase I dose-escalation study
    Journal Article

    Callahan, M. K.; Kluger, H.; Postow, M. A.; Segal, N. H.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J. M.; Krishnan, S.; Bhore, R.; Horak, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy
    Journal Article

    Khalil, D. N.; Smith, E. L.; Brentjens, R. J.; Wolchok, J. D.
    Nature Reviews Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
    Journal Article

    Holmgaard, R. B.; Zamarin, D.; Lesokhin, A.; Merghoub, T.; Wolchok, J. D.
    EBioMedicine (2016)

    Fulltext@MSK | Save
  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Journal Article

    Belum, V. R.; Benhuri, B.; Postow, M. A.; Hellmann, M. D.; Lesokhin, A. M.; Segal, N. H.; Motzer, R. J.; Wu, S.; Busam, K. J.; Wolchok, J. D.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Tumor immunology and cancer immunotherapy: Summary of the 2014 SITC primer
    Journal Article

    Page, D. B.; Bourla, A. B.; Daniyan, A.; Naidoo, J.; Smith, E.; Smith, M.; Friedman, C.; Khalil, D. N.; Funt, S.; Shoushtari, A. N.; more...
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save